J Biol Chem, Vol. 274, Issue 47, 33251-33258, November 19, 1999
Urea-induced Denaturation of Human Phenylalanine Hydroxylase*
Rune
Kleppe
,
Kathrin
Uhlemann§,
Per M.
Knappskog¶, and
Jan
Haavik
From the
Department of Biochemistry and Molecular
Biology, University of Bergen, N-5009 Bergen and the
¶ Department of Medical Genetics, University of Bergen, Haukeland
Hospital, N-5021 Bergen, Norway
 |
ABSTRACT |
Human phenylalanine hydroxylase was expressed and
purified from Escherichia coli as a fusion protein with
maltose-binding protein. After removal of the fusion partner, the
effects of increasing urea concentrations on enzyme activity,
aggregation, unfolding, and refolding were examined. At pH 7.50, purified human phenylalanine hydroxylase is transiently activated in
the presence of 0-4 M urea but slowly inactivated at
higher denaturant concentrations. Intrinsic tryptophan
fluorescence spectroscopy showed that the enzyme is denatured through
at least two distinct transitions. The presence of phenylalanine
(L-Phe) shifts the transition midpoint of the first
transition from 1.4 to 2.7 M urea, whereas the second transition is unaffected by this substrate. Apparently the free energy
of denaturation was almost identical for the free enzyme and for the
enzyme-substrate complex, but significant differences in
d
GD/d[urea]
(mD values) were observed for the first
denaturation transition. In the absence of substrate, a high rate of
non-covalent aggregation was observed for the enzyme in the presence of
1-4 M urea. All three tryptophan residues in the enzyme
(Trp-120, Trp-187, and Trp-326) were mutated to phenylalanine, either
as single mutations or in combination, in order to identify the
residues involved in the spectroscopic transitions. A gradual dissociation of the native tetrameric enzyme to increasingly denatured dimeric and monomeric forms was demonstrated by size exclusion chromatography in the presence of denaturants.
 |
INTRODUCTION |
Phenylalanine hydroxylase (phenylalanine 4-monooxygenase,
PAH,1 EC 1.14.16.1) is one of
three enzymes constituting the pterin-dependent amino acid
hydroxylase superfamily, all of which catalyze rate-limiting reactions
of several metabolic pathways (1). In particular, loss of hPAH activity
forms the molecular basis for phenylketonuria (PKU), an autosomal
recessive disorder in the amino acid metabolism.
The three hydroxylases, human PAH (hPAH), human tyrosine hydroxylase,
and human tryptophan hydroxylase, appear mainly as homotetrameric enzymes, but hPAH is frequently observed in an L-Phe and
pH-dependent equilibrium between dimeric, tetrameric, and
to some extent higher oligomeric forms (2). Deletion mutagenesis
analysis, proteolytic cleavage analysis (2, 3), and more recently,
x-ray crystallography (4, 5) and infrared spectroscopy (IRS) (6)
indicate a three-domain structure containing an N-terminal regulatory
domain (residues 1-110), which appears to be less structured and more flexible, a more structured,
-helical rich, catalytic domain (residues 111-410), and an oligomerization domain (residues 411-452), which includes a tetramerization motif at the extreme C-terminal end
(residues 428-452).
hPAH contains three tryptophans (Trp-120, Trp-187, and Trp-326) and 22 tyrosine residues (7), which contribute to the characteristic UV
spectroscopic properties of the enzyme. Although the tryptophans contribute the most to its fluorescence, the relative excess of tyrosine residues is clearly reflected by the absorbance maximum, which
appears at 278 rather than 280 nm (8). Recently, the steady state
fluorescence of wild-type hPAH (wt-hPAH) as well as tryptophan
substitution mutants were characterized by Knappskog and Haavik (8),
and their spectroscopic changes upon incubation with L-Phe,
tetrahydrobiopterin, and Fe(II) have been reported.
An enzyme kinetic characterization of many mutants, some of which are
disease-related, has proven difficult, due to their instability,
aggregation, and low yields in conventional expression systems (8, 9).
For most of the PKU-associated mutants, the reason for the decreased
activity is not known, although it is suggested that some of the enzyme
forms suffer from an intrinsic thermodynamic instability (9-12). It is
therefore necessary to obtain more information on the thermodynamic
stability of native wt-hPAH and mutants to estimate its contribution to
PKU, compared with other reasons for reduced activity. For mutants
affecting the protein structure, it will be important to determine
whether folding intermediates or unfolding intermediates are
responsible for the abnormal behavior (13).
It has repeatedly been argued that PKU is a "model genetic disease"
and that PAH is a well characterized enzyme (14). However, there is a
striking lack of information about the thermodynamic properties of
either the wt enzyme or any of the more than 300 different mutants that
are associated with this disease. As a first approximation, we here
present stability data on the wt human enzyme expressed and purified
from Escherichia coli. Chehin et al. (6) have
performed thermal stability analyses on wild-type and truncated forms
of hPAH using IRS, verifying the existence of interactions between the
N-terminal and catalytic domain, but the free energy of unfolding has
previously not been addressed.
In this study, solvent denaturation by urea was applied, as this method
has often been found to reversibly unfold proteins and readily give
estimates of their stability (15). Activity measurements, turbidimetric
measurements, fluorescence spectroscopy, and size exclusion
chromatography (SEC) have been used to monitor conformational changes
and oligomeric structure during unfolding of
L-Phe-activated and non-activated hPAH. In order to
localize conformational changes upon denaturation, tryptophan to
phenylalanine mutants were included in these studies.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Guanidine hydrochloride (GdnHCl), potassium
iodide, sodium chloride, sodium thiosulfate, EDTA, and ammonium Fe(II)
sulfate were from Merck. (6R)-Tetrahydrobiopterin was
purchased from Schircks Laboratories (Switzerland). Dithiothreitol
(DTT), catalase, and L-Phe were from Sigma, and urea was
from Fluka. All reagents were of analytical grade.
Expression and Purification--
Recombinant wt- and mutant hPAH
were expressed in E. coli as maltose-binding fusion
proteins, using the pMAL vector system, cleaved, and purified to
homogeneity, in order to remove the tryptophan-rich fusion partner (8,
16). Enzyme concentrations were measured spectrophotometrically using
280 = 1.00 mg
1 ml cm
1 for wt
and 0.63 mg
1 ml cm
1 for the single
tryptophan mutants (8).
Enzymatic Activity--
PAH activity was measured as described
by Martinez et al. (16), using an assay mixture containing 1 mM L-Phe, 0.1 M Na-Hepes, pH 7.5, 0.2 M NaCl, 1 mg ml
1 catalase, 0-8
M urea, 2.0 µg of enzyme, and 5 mM DTT, 100 µM (NH4)2Fe(II)SO4
and 75 µM (6R)-tetrahydrobiopterin in a final reaction volume of 100 µl and stopped with an equal amount of 1%
(v/v) acetic acid in ethanol. The amount of L-tyrosine
formed was determined using high performance liquid chromatography
(17).
Equilibrium Denaturation--
The enzyme samples were incubated
in darkness at 25 °C for 18 h in 0.2 M NaCl, 0.1 M Na-Hepes, pH 7.5, and 0-8 M urea. EDTA (1.25 mM) was added to prevent the quenching of fluorescence by metal ions (18). Buffer solutions were filtered through a 0.22-µm syringe filter before use.
Fluorescence Measurements--
All data were obtained on a
Perkin-Elmer 50B fluorimeter with a constant temperature cell holder
with maximal stirring at 25 °C. Intrinsic tryptophan fluorescence
was measured using excitation at 295 nm (slit 6 nm) and emission from
300 to 460 nm (slit 4 nm) with a scan speed of 240 nm s
1.
Similarly, intrinsic tryptophan and tyrosine fluorescence were measured
in the emission range 280 to 460 nm upon excitation at 275 nm. Protein
concentrations were kept at less than 0.1 mg ml
1, in
order to minimize the inner filter effect (A295
<0.02). Fluorescence quenching experiments were performed by the
stepwise addition of quenching solution (5 M KI containing
10 mM Na2S2O3 to
prevent oxidation of iodide to I2 (19)) to the solution of
denatured hPAH. The fluorescence quenching data were analyzed according to the Stern-Volmer and the modified Stern-Volmer equations (20).
Aggregation2--
Protein
aggregation was estimated by measuring optical density at 340 nm, where
soluble PAH has a low absorbance (1). Measurements were performed at
25 °C using a 8452A diode array spectrophotometer from
Hewlett-Packard.
Size Exclusion Chromatography (SEC)--
The molecular
dimensions of native and denatured hPAH were estimated using an
Amersham Pharmacia Biotech Superdex 200 HR 30/10 column and a Bio-Rad
BioLogic HR chromatography system. The buffer was pumped at a flow rate
of 0.50 ml min
1, and the column was calibrated using
proteins with Stokes radii taken from the literature as compiled by
Uversky (21) and Corbett and Roche (22). Blue dextran and acetone were
used to determine the void volume (V0) and the
total liquid volume inside the column (Vt),
respectively. Small variations in V0 and
Vt at different denaturant concentrations were used
to correct the observed elution volume of the samples as previously
reported (21). The following proteins were used for column calibration: cytochrome c, RNase I, ovalbumin, bovine serum albumin,
yeast alcohol dehydrogenase, catalase, apoferritin, and thyroglobulin. The enzyme samples were incubated from 10 min to 3 days at 40 µg/ml
at room temperature (21 °C) in 100 mM Na-Hepes, pH 7.50, containing 200 mM NaCl, 1.25 mM EDTA, either
with or without 0.5 mM L-Phe and from 0-8
M urea and/or 0-3 M GdnHCl. Addition of 10 mM DTT was used to test for disulfide cross-linking. Prior to application on the column, all samples were filtered through a
0.22-µm syringe filter. The chromatograms were resolved into different components using the exponentially modified gaussian equation
available in Peakfit (SPSS Inc.).
Modeling wt-PAH Stability--
Three-state fits were applied to
the spectroscopic transitions, and the fraction of native,
intermediate, and denatured enzyme was determined at each urea
concentration. The linear extrapolation method (23) was used to
calculate the thermodynamic stability in the absence of denaturant
according to the Equations 1-4.
|
(Eq. 1)
|
|
(Eq. 2)
|
|
(Eq. 3)
|
|
(Eq. 4)
|
Where i, j, = 1 corresponds to the native
state; i, j = 2 the intermediate state; and
i, j = 3 the unfolded state.
si is the signal contribution of state i
at the applied protein concentration; xi is the
molar fraction of component i at the denaturant concentration d, and Sobs is the
observed fluorescence signal. Kij is the equilibrium
constant of the transition i to j, and
Q is the partition function of the system (= 1 + K12 + K12K23); R is
the gas constant; T the temperature (in Kelvin);
GDijH2O
is the free energy of denaturation without denaturant present for the
i to j transition; and mDij is
the corresponding denaturant concentration index in the linear
extrapolation method (see Equation 4). Linear variations of
si were included in the calculations by linear
regression of observations at denaturant concentrations where more or
less pure states were observed. Sigma Plot (Jandel Scientific Corp.)
was used for fitting the three-state model to the observed data.
 |
RESULTS |
Activity Measurements--
The activity of hPAH was measured after
urea or GdnHCl denaturation, performed in the presence or absence of
its amino acid substrate. As both denaturants had qualitatively similar
effects on PAH activity, only the urea measurements are presented in
Fig. 1. Depending on assay conditions,
L-Phe is known to increase the specific activity of
mammalian PAH severalfold when the enzyme is preincubated with this
substrate for some minutes before catalysis (1). This activation of
native hPAH is evident from Fig. 1 at low urea concentrations, but it
is absent after 10 min incubation in 4 M urea. Upon
denaturation in the presence of L-Phe, an almost linear
loss in activity was observed with increasing urea concentrations, whereas in the absence of the amino acid a transient activation of hPAH
at urea concentrations ranging from 0.5 M to 3 M was obvious. Still, the specific activity of
urea-activated PAH was always lower than the substrate-activated
enzyme. Interestingly, a marked minimum in the urea activation of PAH
activity was apparent at urea concentrations ranging from approximately
1.5 to 2.5 M after only 10 min incubation and even more so
after 100 min (Fig. 1).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 1.
Pre-equilibrium activity of hPAH.
Relative enzyme activity, after preincubation of wt-PAH (40 µg/ml) at
different urea concentrations for 10 min in the presence of 0.5 mM L-Phe ( ), expressed as the average of two separate
measurements and for 10 ( ) or 100 min ( ), in the absence of
L-Phe, both expressed as the means of eight separate
measurements ± S.E. After preincubation for 10 or 100 min, either
in the absence or presence of 0.5 mM L-Phe, the reaction
was initiated by the addition of 5 µl of enzyme to 95 µl of assay
mixture (see "Experimental Procedures"). Inset, kinetics
of inactivation of wt-PAH (40 µg/ml) upon incubation at different
urea concentrations (no L-Phe) plotted as remaining
relative activity relative to nondenatured enzyme: no urea ( ), 0.5 M urea ( ), 2.5 M urea ( ). Assay
conditions were as described under "Experimental Procedures," but
PAH was preincubated in presence of 1 mM L-Phe as described
(18).
|
|
Enzyme Aggregation--
It has been reported that wt-PAH (16) and,
in particular, mutant forms of the enzyme (8-12) have a tendency to
aggregate in vitro. Using a diode array spectrophotometer,
hPAH aggregation was estimated as turbidity at 340 nm at different urea
concentrations (Fig. 2) and protein
concentrations (data not shown). At urea concentrations where a
significant aggregation was observed, the time course of the scattering
intensity showed a sigmoidal shape (not shown), as is commonly observed
(24, 25). For each experiment, the maximal rate of aggregation
((dA340/dt)max) was
determined. As expected, increasing protein concentrations gave
increasing rates and extent of aggregation. At constant protein
concentration, the rate of PAH aggregation showed a distinct maximum
between 1.5 and 2 M urea (Fig. 2). In the presence of
0.5 mM L-Phe, the empirical rate of
aggregation was only 2% of the rate in the absence of the substrate
(Fig. 2). However, turbidity data are not easily interpreted at a
molecular level or in kinetic terms (24). Thus, turbidity measurements
as performed here may not be suitable for the detection of low
molecular weight aggregates. The aggregated protein could be dissolved
in high concentrations of urea (data not shown), demonstrating the
noncovalent interactions of the aggregates.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 2.
Empirical rate of aggregation of wt-PAH at
different urea concentrations. Turbidity
(A340 nm) was measured as a function of time at
different urea concentrations. The maximal rate of aggregation was
determined for each curve. The concentration of PAH was 80 µg
ml 1 at all urea concentrations both in absence ( ) and
presence ( ) of 0.5 mM l-Phe.
|
|
Fluorescence Measurements--
As PAH is subject to aggregation in
the presence of denaturants, fluorescence spectroscopy was selected for
monitoring denaturation, since it can be performed at very low protein
concentrations, where aggregation is minimized. As observed for
activity measurements (Fig. 1), the changes in hPAH fluorescence
induced by urea denaturation occurred slowly. Thus, all fluorescence
measurements were performed after incubation for 18 h at 25 °C,
which appeared sufficient to reach a steady signal.
Representative emission spectra obtained from equilibrium denaturation
of nonactivated wt-hPAH are shown in Fig.
3A. Two different parameters,
fluorescence intensity at 345 nm and the ratio of the fluorescence
intensities at 355 nm versus 337 nm
(I355/I337), were used to monitor
denaturation. The ratio method had the advantage of being less
susceptible to small variations in protein concentrations between
experiments and reflects mainly the shifts in emission maxima upon
denaturation, due to changes in polarity of the local environment
surrounding tryptophan. However, as the observed fluorescence ratio is
not strictly linear in terms of the molar fraction of the existing
states, only the fluorescence intensity at 345 nm was used for model
fitting (26). As shown in Fig. 4, two
transitions were obvious for denatured non-activated and
L-Phe-activated hPAH. Both spectroscopic parameters
increased in a linear fashion with changes in urea at concentrations
flanking the transition regions, as is normally observed for pure
states (26).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
Fluorescence spectra of wt and mutant
hPAH. Tryptophan emission spectra, excitation at 295 nm, of
equilibrium denatured, nonactivated wt-PAH at different urea
concentrations (A); no urea (line 1), 4 M urea (line 2), and 7 M urea
(line 3). Tyrosine-tryptophan emission spectra, excitation
at 275 nm, of equilibrium denatured, nonactivated wt-PAH, W187F/W326F
and W120F/W326F (B): wt-PAH at 4 M urea
(line 1), W187F/W326F at 4 M urea
(line 2), W120F/W326F at 4 M urea (line
3), wt-PAH at 7 M urea (line 4),
W187F/W326F at 7 M urea (line 5), and
W120F/W326F at 7 M urea (line 6). The
protein concentration was 40 µg ml 1.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 4.
Equilibrium denaturation of wt-PAH.
Denaturation was monitored by fluorescence intensity at 345 nm
(A) and by ratio of relative fluorescence intensities at 355 nm and 337 nm (B), expressed as means of two to five
measurements. Both nonactivated ( ) and activated ( ) hPAH (40 µg
ml 1) are presented. Straight dotted lines in
A represent linear least square fit of points determined to
lie outside the transition regions. Black dots corresponding
to observed intensities account for values calculated on the basis of
the obtained
GDijH2O and
mDij values (see "Experimental
Procedures").
|
|
For hPAH incubated in the absence of amino acid ligand, increasing the
urea concentration from 0.9 to 4 M resulted in a 75% increase in the tryptophan fluorescence intensity (Fig. 3A).
This transition was accompanied by an approximately 2 nm red-shift in
fluorescence emission maximum. Incubation with L-Phe prior to denaturation gave a more modest increase in fluorescence intensity (45%) and 6 nm blue shift in the emission maximum during the first transition. The two partially denatured states had similar fluorescence properties but a shift toward higher urea concentrations was observed in the midpoint for the transition of the activated native state to intermediate.
At higher urea concentrations PAH showed a loss in fluorescence
intensity (approximately 25%), as well as a 10 nm red-shift in
fluorescence intensity maximum both in the presence and absence of
L-Phe. No differences in urea concentration of the
denaturation midpoints were evident, which indicates that the ligand
does not have any effect on the intermediate.
Fluorescence Quenching Studies--
In order to address the
fluorescence changes during unfolding and monitor the solvent exposure
of indole moieties, fluorescence quenching studies by the ionic
quencher iodide were performed. In addition, changes in indole
fluorescence maximum may arise from other conformational changes,
increasing the local environment polarity surrounding tryptophan (19).
Quenching data recorded at several urea concentrations were plotted
according to the Stern-Volmer equation (20). A downward deviation of
the Stern-Volmer curves was observed in all experiments, as expected
for a heterogeneous population of fluorophores. By using the modified
Stern-Volmer equation, linear quenching plots were obtained. Only
moderate changes in accessibility of the tryptophan residues to
quenchers were observed during the first transition (up to 4 M urea), indicating minor opening of the core
structure of hPAH, whereas a further increase of the urea concentration
to 6.5 M resulted in an increased solvent exposure of
the tryptophan(s) (Fig. 5). However, the
theoretical limit of complete accessibility (fa = 1)
was not attained even in 8 M urea.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
Solvent exposure of tryptophan residues
during denaturation. Fraction of tryptophans accessible to
quenching by iodide at different urea concentrations (40 µg
ml 1 protein concentration). Each point in the
graph is calculated from the modified Stern-Volmer equation for a
quenching experiment on the respective sample. The dotted
curve is not based on calculations.
|
|
Denaturation studies were also performed on the W120F/W326F and
W187F/W326F mutants of hPAH (in the following referred to as hPAH-W187
and hPAH-W120, respectively). Both showed similar fluorescence changes
at higher urea concentrations compared with wt enzyme, i.e.
a large red shift of the tryptophan emission maxima and a loss in
tryptophan fluorescence intensity as well as an increased solvent
exposure of the tryptophan residues (data not shown). The greater
tendency toward aggregation, as well as differences in fluorescence
changes during denaturation, indicate that the mutants are considerably
less stable than the wt enzyme and can give only qualitative
information on conformational changes of wt-PAH at a given urea
concentration. As already shown by Knappskog and Haavik (8) at
nondenaturing conditions, Trp-120 was the major contributor to
fluorescence intensity also during denaturation and was especially
dominating at urea concentrations below 4 M (data not shown).
At higher urea concentrations both mutants shifted their emission
maximum to the same wavelength as the wild-type enzyme, but only
hPAH-W187 seemed to increase its solvent exposure to the same extent as
wt-hPAH (data not shown). The lower increase in fa
for hPAH-W120 may be due to the presence of polar residues around the
tryptophan other than the solvent. This is possibly the case for wt and
hPAH-W187 too, as neither of them show complete solvent exposure
despite their highly red-shifted spectra. However, the charged
environment surrounding the tryptophans may also influence the
accessibility to quenching by iodide. The incomplete accessibility of
iodide is also compatible with the presence of some residual structure
even in 8 M urea (see below). Experiments on the
W120F/W187F mutant were not included in this study, as this mutant
gives very low yield during purification and rapidly aggregates
(8).
Simultaneous Tyrosine and Tryptophan Excitation--
At high urea
concentrations tyrosine fluorescence was more pronounced for wt hPAH,
due to a red shift of the tryptophan emission maximum and a decrease in
tryptophan fluorescence intensity. This could be due to an increased
distance between the fluorophores, followed by lower energy transfer
between tyrosine and tryptophan residues in the course of denaturation
(Fig. 3B). Tyrosine fluorescence is insensitive to changes
in the polarity of its environment (19), meaning that its emission
maximum at 303 nm will be constant throughout the range of urea
concentrations, irrespective of solvent effects and changes in its
local side chain environment. Comparison between wt and mutants has
clearly shown that replacing two tryptophan residues increases the
tyrosine fluorescence at 4 M and especially at 7 M urea. Tryptophan-tyrosine emission spectra of wt
enzyme at 4 M urea were completely dominated by
tryptophan fluorescence (Fig. 3B). However, in 7 M urea a distinct emission peak appeared at 305 nm.
This indicates that tyrosine fluorescence is not only superimposed by
tryptophan but does appear as tryptophan fluorescence due to energy
transfer or is due to the formation of nonfluorescent complexes. At
least at 4 M urea, tyrosine fluorescence of the mutants was significant upon excitation at 275 nm and finally dominated
over tryptophan fluorescence in the spectrum of Trp-187 at 8 M urea. It may be concluded that Trp-187 is a less
effective quencher of tyrosine fluorescence than the other tryptophan residues.
Determination of Thermodynamic Parameters--
The most obvious
interpretation of the denaturation profiles (Fig. 4) was a three-state
denaturation for both substrate-activated and non-activated hPAH. The
experimental data were fitted to this model as described under
"Experimental Procedures" (black dots in Fig.
4A), and the results are summarized in Table
I. As seen from the table, the transition
midpoint of the first transition (state 1 to 2) was shifted upwards by
1.3 M urea in the presence of 0.5 mM
l-Phe. However, no significant difference in
GD12H2O
values was obtained by these measurements, instead the shift was
reflected in the mD12 values. The parameters of the second transition (state 2 to 3) were similar irrespective of the
presence of L-Phe, within the errors given by these
measurements.
View this table:
[in this window]
[in a new window]
|
Table I
Thermodynamic parameters for the urea denaturation of wt PAH
The free energy change of unfolding for the two transitions under
physiological conditions,
GDijH2O,
was determined based on fluorescence intensity as described under
"Experimental Procedures" (Equations 1-4). Cmij
represents the urea concentration at the transition midpoint. Values
are given ± S.E. obtained in the nonlinear fitting, except those
for Cmij, which are calculated from the obtained
error limits.
|
|
SEC of Denatured hPAH--
Based on the effects of urea on the
elution volumes of PAH, a model for the stepwise dissociation and
denaturation of this enzyme has been developed (Table
II). Going from no urea to high denaturing conditions, the chromatograms were resolved into several components by adding new ones, preferably according to a two-state model for each transition (fluorescence data), whenever the components resolved at lower urea concentration did not suffice in the fitting. However, the interpretation of the SEC data was not unequivocal, due to
the multiple oligomeric forms observed and in some cases the
overlapping retention times of these species.
In the absence of L-Phe and urea, the majority of hPAH
eluted with a volume corresponding to the tetramer, with a minor
proportion corresponding to the octamer and dimer species (Table II and
Fig. 6). By addition of
L-Phe, the oligomeric state was shifted toward tetrameric
and octameric PAH, as has previously been reported (1, 16). The
observed tetrameric sizes for both nonactivated and substrate-activated
hPAH (with Stokes radii of 53 and 54 Å, respectively) were almost
identical to the values of previously reported SEC measurements of rat
PAH (27) (55 and 57 Å, respectively).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 6.
Size exclusion chromatography of denatured
PAH. Selected urea concentrations (0, 2, 4, 6, and 7 M) with the different resolved components shown as
thin lines are represented. Trace numbers 1, 3, 5, and 7 correspond to nonactivated hPAH at 0, 2, 4, and 7 M urea, respectively. Trace numbers 2, 4, 6, and 8 correspond to L-Phe activated hPAH
at 0, 2, 4, and 6 M urea, respectively. The scaling
on the Stokes radius axis was calculated from the calibration curve. A
protein concentration of 40 µg ml 1 was used in these
experiments.
|
|
The presence of low urea concentrations had a destabilizing effect on
tetrameric and octameric PAH in favor of the dimer both in the absence
and presence of L-Phe (Table II). However, in the presence
of the substrate the transition to dimer appeared at higher urea
concentrations (between 3 and 4 M urea). Below 4 M urea, components of both native and partially
denatured dimer and tetramer could be resolved. The partially denatured
species had RS values typically 4 Å larger than the
corresponding native oligomer (Table II).
In the presence of 1-3 M urea, a slowly eluting
component was observed for both activated PAH and more so for
nonactivated enzyme (Fig. 6). The retention time for this component
corresponds to a Stokes radius of 32 and 34 Å for nonactivated and
activated PAH, respectively. This is approximately the expected size of monomeric PAH, as calculated from observed sizes of the native tetramers.
At high concentrations of urea a main component was of similar size as
native octameric PAH. Further addition of denaturant (3 M GdnHCl) further contributed to an increase of the
Stokes radius to 75 Å. At 6 and 7 M urea, small
amounts of partially denatured dimer could be detected. This species
seemed to increase in size at higher urea concentrations (Table II).
The presence of 10 mM DTT had no effect on the
calculated Stokes radius of PAH in the presence of denaturants.
Reversibility of Transitions--
Partial reversibility (50-90%)
of the second spectroscopic transition was achieved by diluting the
enzyme from 8 M urea to 4-7 M
final concentrations of urea (data not shown). However, more detailed
studies are needed to determine whether further reversibility of PAH
denaturation is possible.
 |
DISCUSSION |
Activation and Denaturation of PAH--
The enzyme activation
observed upon exposure to moderate concentrations of urea or GdnHCl was
similar to findings on the rat (r) enzyme (28), although rPAH was
activated to a much larger extent. Parniak (28) has suggested that low
concentrations of denaturant provoke conformational changes similar to
those noted upon substrate-induced activation and reflect the
denaturation of an "inhibitory domain" (28). Although this is an
interesting hypothesis, spectroscopic data presented here clearly show
that these processes are distinct. Instead of the 10 nm red shift and 15% increase in quantum yield observed by L-Phe activation
(8), a modest 2 nm red shift and an 80% increase in fluorescence
intensity was observed going from 0 to 3 M urea.
Furthermore, the urea-treated enzyme had fluorescence spectra clearly
different from those of the N-terminal deletion mutants (2), which have
a diminished or abolished inhibitory effect of the N-terminal domain.
Partial Denaturation of hPAH--
The activity measurements in the
absence of urea show a partial inactivation of hPAH during the long
incubations used in these studies. However, loss of activity does not
seem to be reflected in the fluorescence measurements. Furthermore, SEC
experiments at nondenaturing conditions show that PAH retains many of
its native properties after such periods of time, including its
compactness and oligomer equilibria. Partial denaturation of hPAH
occurs between 0.7 and 2.5 M urea in the
absence of L-Phe and between 1 and 4 M
urea in the presence of this substrate, as reflected in the fluorescence intensities at 345 nm and by the fluorescence intensity ratios (Fig. 4). Partially denatured tetrameric and dimeric PAH were
found both in the presence and absence of L-Phe. However, it was not possible to explain the chromatograms by pure two-state transitions, as some volume changes were evident from the appearance to
the disappearance of the partially denatured species (Table II). Thus,
some degree of variability is likely for the partially denatured
states. The appearance of variable states in solvent denaturation
studies has been reported frequently (22, 29, 30). The tryptophan
quenching studies on PAH support the above observations: a minor volume
increase during the first transition (relative to the second) and some
degree of variability of the intermediate state.
The large effect on Trp-120 fluorescence as well as the activation of
PAH is consistent with a denaturation of the N-terminal domain at low
urea concentrations. The crystal structure of dimeric rPAH (residues
19-427) (31) shows a covering of the active site by the far N-terminal
residues, which also may prevent efficient binding and enzymatic
conversion of L-Phe. However, a partial denaturation of the
N-terminal domain is unlikely to be causing the observed shift in
oligomeric structure toward dimeric (and some monomeric) PAH below 4 M urea. Deletion mutation studies on hPAH (2) have
shown that removal of the N-terminal does not dissociate the tetramer
into dimers. Pure dimeric PAH was generated when residues 429-452,
corresponding to the
-helix (
14) in the tetramerization motif
(5), were deleted. Thus, the observed effects of urea could be due to
conformational changes at the far C terminus during partial
denaturation of hPAH. The appearance of a partially denatured tetramer
for both nonactivated and activated PAH suggests that alterations in
the C terminus requires higher concentrations of urea than the
suggested N-terminal alterations.
Turbidity measurements showed that the rate of aggregation is dependent
on protein (not shown) and urea concentration (Fig. 2). The increased
rate of aggregation at intermediate urea concentrations coincides well
with the observed decrease of activation observed between 1 and 3 M urea. However, as the activity at 2 M urea after 100 min incubation does not markedly
differ from that at nondenaturing condition, aggregation probably does
not influence the activity of PAH to a large extent. The identification
of the aggregating species is not a trivial task. In the SEC
experiments, aggregation was evident in the presence of 4 M urea, where only the denatured dimeric PAH was
found. Whereas this is a likely candidate for an aggregating species
under these conditions, other partially denatured forms of the protein
probably also aggregate.
Attempted Complete Unfolding of PAH--
Denaturation of the
partially denatured dimer was observed above 4.5 M
urea and was, by fluorescence intensity measurements, apparently
completed above 6.5 M urea. However, a further
increase in volume is observed above this urea concentration. In fact, even in the presence of 8 M urea supplemented with
1.5 M GdnHCl and 10 mM DTT, the
unfolding is incomplete, which shows the high degree of variability of
this state. Only monomeric PAH can be expected to exist at such
denaturing conditions. Hence, a concomitant unfolding of dimeric and
dissociation to monomeric PAH is suggested. A sequential dissociation
and unfolding would be expected to give monomeric non-unfolded
components at 4-6 M urea, which is not observed.
An approximate 30-Å increase in Stokes radius is observed between 4 and 6 M urea, with a further 10-Å increase at 8 M urea supplemented with 3 M
GdnHCl. This represents a rough 12× volume increase of the monomer
relative to that at non-denaturing conditions (estimated as one-fourth
of the observed tetramer volume). Such a large volume increase is not
unexpected for a protein with a chain length of 439 amino acids.
Monomer volume ratios above 8 between observations in 6 M GdnHCl and native conditions are common even for
small monomeric proteins (21).
The above discussion suggests a minimal three-state model for the
denaturation of hPAH. However, in their study on the thermal stability
of hPAH using IRS, Chehin et al. (6) reported only one
transition for wt-PAH. We suggest that their observation corresponds to
the second transition, or the unfolding of PAH in this study, and that
possible intermediates remain undetected as the IRS study focused on
changes in
-helix content.
Calculations of the Thermodynamic Parameters--
A three-state
model was assumed for the unfolding of hPAH, as this adequately
explained the observed fluorescence changes. However, the complexity of
the changes in oligomeric structure during denaturation makes it
virtually impossible to incorporate quantitatively all these effects
into the denaturation model. Thus, the model fitted to the fluorescence
data does not consider aggregation or changes in oligomeric structure.
Because of this, the calculated thermodynamic parameters (Table I), as
well as the apparent cooperativity, would be expected to depend on
experimental conditions, in particular protein concentrations. Such
deviations from ideality could influence the presented thermodynamic
parameters in various ways. Furthermore, our preliminary experiments
have not shown complete reversibility of the spectroscopic transitions. Thus, we are dealing with a pseudo-equilibrium system for which microreversibility has been assumed.
As shown, despite the approximate 1.3 M shift in
Cm12 between nonactivated and
L-Phe-activated PAH, there seems to be little difference in
their free energy of denaturation. Instead, the
Cm12 shift is reflected in the different
mD12 values, which is approximately 2-fold
larger for the nonactivated compared with the activated enzyme. Based
on a model analogous to Gibbs absorption isoterm, it has been suggested
that the mD value in the linear extrapolation method
is proportional to the surface area exposed during denaturation
(
A) (32). However, this relationship does not seem to
apply for the partial denaturation of PAH, as both nonactivated and
activated PAH have similar Stokes radii at 4 M urea
and similar native structures. There are, however, a number of
differences between the nonactivated and activated enzymes in the
transition regions, which may substantially influence the observed
thermodynamic parameters, including their oligomeric structures and
aggregation properties. Furthermore, the interpretation of the
mD value in terms of
A has been
claimed to be oversimplified (30).
The parameters for the second transition were more or less equal for
activated and nonactivated enzyme, as expected for the unfolding of
equal intermediate states. However, the variable nature of the unfolded
state might play a significant role when extrapolating the
GD23 to nondenaturing conditions. Lack of nonlinearity in the extrapolation method might give erroneous estimates of
GD23H2O,
a weakness criticized in the literature (30, 33, 34).
PAH Stability and Its Importance in PKU--
Several reports exist
on PAH mutant proteins, many of which are mutations associated with
PKU. Many of the proteins show a high degree of instability and
susceptibility toward aggregation and degradation (8, 9, 10, 11, 12,
35). The low stability of PAH toward partial denaturation and the
observed aggregation at low urea concentrations could imply a role of
this state in the understanding of PKU-related mutations (36). However, thorough denaturation studies have not been performed on any
PKU-associated mutants, and these proteins may behave differently.
Furthermore, several technical problems, including protein aggregation,
must be resolved before such comparable analysis can be performed.
Recent studies on protein stability and engineering point toward the
importance of the denatured state ensemble for understanding the native
state stability (31, 32, 37). Searching for causes of decreased (or
increased) stability of mutants in the native structure alone will
probably fail in most cases, because such a reasoning implies that the
denatured states behave as random coils in vivo, a
hypothesis that has been negated by numerous observations (30, 38, 39).
In particular, the denatured states of PAH have been shown to be fairly
compact and hence contain many native-like interactions. As shown here,
a complete random coil of PAH was not found even in 8 M urea supplemented with 3 M GdnHCl
and 10 mM DTT.
 |
ACKNOWLEDGEMENTS |
We are grateful for expert technical
assistance from Sidsel E. Riise and Ali J. S. Munoz and for helpful
suggestions on the manuscript from Dr. Aurora Martínez and
Matthias Thórólfsson.
 |
FOOTNOTES |
*
This work was supported by grants from The Research Council
of Norway.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Dept. of Biochemistry and Biotechnology,
Martin-Luther-University Halle-Wittenberg, 06120 Halle/Saale, Germany.
To whom correspondence should be addressed. Tel.:
47-55-586432; Fax: 47-55-586400; E-mail: jan.haavik@pki.uib.no.
2
Aggregation in this text refers to the formation
of non-native higher molecular weight species from non-native units. In
contrast, association describes the formation of native higher
molecular weight species from native or native-like (as in refolding) units.
 |
ABBREVIATIONS |
The abbreviations used are:
PAH, L-Phe hydroxylase;
hPAH, human PAH;
wt-PAH, wild-type PAH;
rPAH, rat PAH;
hTPH, human tryptophan hydroxylase;
DTT, dithiothreitol;
IRS, infrared spectroscopy;
SEC, size exclusion chromatography;
GdnHCl, guanidine hydrochloride;
wt, wild type;
PKU, phenylketonuria;
the
abbreviations W120F/W326F and W187F/W326F represent mutant proteins, in
which tryptophan residues were replaced by phenylalanine
residues.
 |
REFERENCES |
| 1.
|
Kappock, T. J.,
and Caradonna, J. P.
(1996)
Chem. Rev.
96,
2659-2756[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Knappskog, P. M.,
Flatmark, T.,
Aarden, J. M.,
Haavik, J.,
and Martinez, A.
(1996)
Eur. J. Biochem.
242,
813-821[Medline]
[Order article via Infotrieve]
|
| 3.
|
Lohse, D. L.,
and Fitzpatrick, P. F.
(1993)
Biochem. Biophys. Res. Commun.
197,
1543-1548[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Erlandsen, H.,
Fusetti, F.,
Martinez, A.,
Hough, E.,
Flatmark, T.,
and Stevens, R. C.
(1997)
Nat. Struct. Biol.
4,
995-1000[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Fusetti, F.,
Erlandsen, H.,
Flatmark, T.,
and Stevens, R. C.
(1998)
J. Biol. Chem.
273,
16962-16967[Abstract/Free Full Text]
|
| 6.
|
Chehin, R.,
Thorolfsson, M.,
Knappskog, P. M.,
Martinez, A.,
Flatmark, T.,
Arrondo, J. L.,
and Muga, A.
(1998)
FEBS Lett.
422,
225-230[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Kwok, S. C.,
Ledley, F. D.,
DiLella, A. G.,
Robson, K. J.,
and Woo, S. L.
(1985)
Biochemistry
24,
556-561[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Knappskog, P. M.,
and Haavik, J.
(1995)
Biochemistry
34,
11790-11799[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Bjørgo, E.,
Knappskog, P. M.,
Martinez, A.,
Stevens, R. C.,
and Flatmark, T.
(1998)
Eur. J. Biochem.
725,
1-10
|
| 10.
|
Eiken, H. G.,
Knappskog, P. M.,
Apold, J.,
and Flatmark, T.
(1996)
Hum. Mutat.
7,
228-238[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Okano, Y.,
Eisensmith, R. C.,
Güttler, F.,
Lichter-Konechi, U.,
Konechi, D. S.,
Trefz, F. K.,
Dasovich, M.,
Wang, T.,
Henriksen, K.,
Loo, H.,
and Woo, S. L. C.
(1991)
N. Engl. J. Med.
324,
1232-1238[Abstract]
|
| 12.
|
Ledley, F. D.,
Koch, R.,
Jew, K.,
Beaudet, A.,
O'Brien, W. E.,
Bartos, D. P.,
and Woo, S. L.
(1988)
J. Pediatr.
113,
436-438
|
| 13.
|
Jaenicke, R.,
and Seckler, R.
(1997)
Adv. Protein Chem.
50,
1-59[Medline]
[Order article via Infotrieve]
|
| 14.
|
Levy, H. L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
1811-1813[Free Full Text]
|
| 15.
|
Privalov, P. L.
(1979)
Adv. Protein Chem.
33,
167-241[Medline]
[Order article via Infotrieve]
|
| 16.
|
Martinez, A.,
Knappskog, P. M.,
Olafsdottir, S.,
Døskeland, A. P.,
Eiken, H. G.,
Svebak, R. M.,
Bozzini, M.,
Apold, J.,
and Flatmark, T.
(1995)
Biochem. J.
306,
589-597
|
| 17.
|
Døskeland, A.,
Ljones, T.,
Skotland, T.,
and Flatmark, T.
(1982)
Neurochem. Res.
7,
407-421[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Haavik, J.,
Martinez, A.,
Olafsdottir, S.,
Mallet, J.,
and Flatmark, T.
(1992)
Eur. J. Biochem.
210,
23-31[Medline]
[Order article via Infotrieve]
|
| 19.
|
Lacowicz, J. R.
(1983)
Principles of Fluorescence Spectroscopy
, Plenum Publishing Corp., New York
|
| 20.
|
Lehrer, S. S.
(1971)
Biochemistry
10,
3254-3263[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Uversky, V. N.
(1993)
Biochemistry
32,
13288-13298[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Corbett, R. J. T.,
and Roche, R. S.
(1984)
Biochemistry
23,
1888-1894[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Pace, C. N.
(1986)
Methods Enzymol.
131,
266-280[Medline]
[Order article via Infotrieve]
|
| 24.
|
De Young, L. R.,
Dill, K. A.,
and Fink, A. L.
(1993)
Biochemistry
32,
3877-3886[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Buchner, J.,
Schmidt, M.,
Fuchs, M.,
Jaenicke, R.,
Rudolph, R.,
Schmid, F.,
and Kiefhaber, T.
(1991)
Biochemistry
30,
1586-1591[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Eftink, M. R.
(1994)
Biophys. J.
66,
482-501[Medline]
[Order article via Infotrieve]
|
| 27.
|
Kappock, T. J.,
Harkins, P. C.,
Friedenberg, S.,
and Caradonna, J. P.
(1995)
J. Biol. Chem.
270,
30532-30544[Abstract/Free Full Text]
|
| 28.
|
Parniak, M. A.
(1989)
in
Chemistry and Biology of Pteridines
(Curtius, H.-C.
, Ghisla, S.
, and Blau, N., eds)
, pp. 656-659, Walter de Gruyter, Berlin
|
| 29.
|
Baskakov, I. V.,
and Bolen, D. W.
(1998)
Biochemistry
37,
18010-18017[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Dill, K. A.,
and Shortle, D.
(1991)
Annu. Rev. Biochem.
60,
795-825[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Kobe, B.,
Jennings, I. G.,
House, C. M.,
Michell, B. J.,
Goodwill, K. E.,
Santarsiero, B. D.,
Stevens, R. C.,
Cotton, R. G. H.,
and Kemp, B. E.
(1999)
Nat. Struct. Biol.
6,
442-448[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Shortle, D.
(1995)
Adv. Protein Chem.
46,
217-247[Medline]
[Order article via Infotrieve]
|
| 33.
|
Johnson, C. M.,
and Fersht, A. R.
(1995)
Biochemistry
34,
6795-6804[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Ibarra-Molero, B.,
and Sanchez-Ruiz, J. M.
(1996)
Biochemistry
35,
14689-14702[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Waters, P. J.,
Parniak, M. A.,
Hewson, A. S.,
and Scriver, C. R.
(1998)
Hum. Mutat.
12,
344-354[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Stigter, D.,
and Dill, K. A.
(1993)
Fluid Phase Equilibria
82,
237-249[CrossRef]
|
| 37.
|
Shortle, D.
(1996)
FASEB J.
10,
27-34[Abstract]
|
| 38.
|
Bierzynski, A.,
and Baldwin, R. L.
(1982)
Eur. J. Biochem.
206,
15-21[Medline]
[Order article via Infotrieve]
|
| 39.
|
Amir, D.,
and Haas, E.
(1988)
Biochemistry
27,
8889-8893[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.